Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER IMMUNOTHERAPY

CAR T cells reach clinical milestone in prostate cancer

Armored CAR T cells show early signs of clinical activity in patients with castration-resistant prostate cancer, paving the way for further development and optimization.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Mechanism of PSMA-directed, TGF-β-armored CAR T cells in castrate-resistant prostate cancer.

References

  1. Narayan, V. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01726-1 (2022).

    Article  PubMed  Google Scholar 

  2. Rosa, K. OncLive https://www.onclive.com/view/p-psma-101-elicits-encouraging-responses-in-metastatic-castration-resistant-prostate-cancer (September 2021).

  3. Neelapu, S. S. Blood 133, 1799–1800 (2019).

    CAS  Article  PubMed  Google Scholar 

  4. Fabrizio, V. A. et al. Blood Adv. https://doi.org/10.1182/BLOODADVANCES.2021006418 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dorff, T. B. et al. Clin. Cancer Res. 28, 576–584 (2022).

    CAS  Article  PubMed  Google Scholar 

  6. Stultz, J. & Fong, L. Prostate Cancer Prostatic Dis. 24, 697 (2021).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Biasco, L. et al. Nat. Cancer 2, 629–642 (2021).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (accessed February 2022).

  9. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (accessed February 2022).

  10. Rafiq, S., Hackett, C. S. & Brentjens, R. J. Nat. Rev. Clin. Oncol. 17, 147–167 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Netto, G. J. & Epstein, J. I. in Diagnostic Immunohistochemistry 3rd edn. (ed. Dabbs, D. J.) 593–661 (Elsevier, 2011).

  12. Fan, A. C. & Leppert, J. T. JAMA Netw. Open 2, e199233 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James L. Gulley.

Ethics declarations

Competing interests

N.P.T., S.M.N. and J.L.G. are employees of the National Cancer Institute, US National Institutes of Health.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tschernia, N.P., Norberg, S.M. & Gulley, J.L. CAR T cells reach clinical milestone in prostate cancer. Nat Med 28, 635–636 (2022). https://doi.org/10.1038/s41591-022-01742-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01742-1

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing